🇺🇸 FDA
Pipeline program

Ropeginterferon alfa-2b

A23-302

Phase 3 mab active

Quick answer

Ropeginterferon alfa-2b for Primary Myelofibrosis is a Phase 3 program (mab) at PharmaEssentia with 1 ClinicalTrials.gov record(s).

Program details

Company
PharmaEssentia
Indication
Primary Myelofibrosis
Phase
Phase 3
Modality
mab
Status
active

Clinical trials